Target Validation Information
TTD ID	T48268
Target Name	Melatonin receptor type 1B (MTNR1B)
Type of Target	Successful
Drug Potency against Target	Ramelteon	Drug Info	Ki = 112 nM	[7]
	2-iodo-melatonin	Drug Info	Ki = 0.16 nM	[1]
	5-methoxycarbonylamino-N-acetyltryptamine	Drug Info	IC50 = 4000 nM	[4]
	Beta,beta-dimethylmelatonin	Drug Info	Ki = 2.75 nM	[3]
	Beta-methylmelatonin	Drug Info	Ki = 2.94 nM	[3]
	N-(2,3,4,9-Tetrahydro-1H-carbazol-3-yl)-acetamide	Drug Info	Ki = 5350 nM
	N-(2-(5-methoxybenzofuran-3-yl)ethyl)acetamide	Drug Info	IC50 = 0.7 nM	[4]
	N-(3-(2,5-dimethoxyphenyl)propyl)acetamide	Drug Info	Ki = 26.1 nM	[6]
	N-(3-(2-ethoxy-5-methoxyphenyl)propyl)acetamide	Drug Info	Ki = 1.59 nM	[6]
	N-(3-(2-hydroxy-5-methoxyphenyl)propyl)acetamide	Drug Info	Ki = 46.2 nM	[6]
	N-(3-(3-methoxyphenyl)-3-phenylallyl)acetamide	Drug Info	Ki = 2.5 nM	[5]
	N-(3-(3-methoxyphenyl)propyl)acetamide	Drug Info	Ki = 0.751 nM	[6]
	N-(3-(3-methoxyphenyl)propyl)propionamide	Drug Info	Ki = 7.07 nM	[6]
	N-(3-(4-hydroxy-3-methoxyphenyl)propyl)acetamide	Drug Info	Ki = 12.6 nM	[6]
	N-(3-(5-methoxy-2-propoxyphenyl)propyl)acetamide	Drug Info	Ki = 2.12 nM	[6]
	N-(3-Benzooxazol-7-yl-propyl)-acetamide	Drug Info	Ki = 4.3 nM	[2]
	N-(3-Benzooxazol-7-yl-propyl)-butyramide	Drug Info	Ki = 3.7 nM	[2]
	N-(3-Benzooxazol-7-yl-propyl)-propionamide	Drug Info	Ki = 1.8 nM	[2]
	N-[3-(2-Ethyl-benzooxazol-7-yl)-propyl]-acetamide	Drug Info	Ki = 2.3 nM	[2]
	UCM-454	Drug Info	Ki = 0.16 nM	[5]
References
REF 1	Synthesis of nitroindole derivatives with high affinity and selectivity for melatoninergic binding sites MT(3). J Med Chem. 2002 Apr 25;45(9):1853-9.
REF 2	Synthesis and structure-activity relationship of novel benzoxazole derivatives as melatonin receptor agonists. Bioorg Med Chem Lett. 2004 Jul 16;14(14):3799-802.
REF 3	Mapping the melatonin receptor. 7. Subtype selective ligands based on beta-substituted N-acyl-5-methoxytryptamines and beta-substituted N-acyl-5-me... J Med Chem. 2006 Jun 15;49(12):3509-19.
REF 4	Design and synthesis of benzofuranic derivatives as new ligands at the melatonin-binding site MT3. Bioorg Med Chem. 2008 May 1;16(9):4954-62.
REF 5	2-[(2,3-dihydro-1H-indol-1-yl)methyl]melatonin analogues: a novel class of MT2-selective melatonin receptor antagonists. J Med Chem. 2009 Feb 12;52(3):826-33.
REF 6	Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2582-5.
REF 7	Therapeutic opportunities from muscarinic receptor research. Trends Pharmacol Sci. 2001 Aug;22(8):409-14.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.